|
|
|
177780 |
 |
BAC-ML "New ASCO data supports Revlimid maintenance.POM renal data supportive of use in patients with moderate and severe renal impairment, a sizeable portion of the myeloma population (30-40%)" |
GN |
Rob Cos |
|
4 |
5/21/2013 10:42:04 PM |
|
| | |
|
177779 |
|
RBC "Pomalyst robust growth trends suggest likely beat of Q2 cons ($42M)" |
GN |
Rob Cos |
|
3 |
5/21/2013 9:40:11 PM |
|
| | |
|
177778 |
|
ASCO "Conclusions: POM + LoDEX significantly extended PFS and OS vs. HiDEX in pts who failed LEN and BORT. POM + LoDEX should become a standard of care in RRMM pts who have exhausted Tx with LEN and BORT" (Can u say EU approval soon) |
GN |
Rob Cos |
|
2 |
5/21/2013 9:37:35 PM |
|
| | |
|
177777 |
|
ASCO "POM + LoDEX significantly extended PFS &OS vs HiDEX in pts with or without moderate Renal Impairment. Tolerability of POM + LoDEX was acceptable across subgroups, with few discontinuations due to AE" |
GN |
Rob Cos |
|
3 |
5/21/2013 9:34:31 PM |
|
| | |
|
177776 |
|
ASCO GIMEMA "Lenalidomide maintenance significantly reduced the risk of progression independently from the previous treatment. OS is similar between MPR and MEL200, with a trend for an improved OS in pts receiving lenalidomide as maintenance therapy" |
GN |
Rob Cos |
|
3 |
5/21/2013 9:31:09 PM |
|
| | |
|
177775 |
|
ASCO"Ph III IMPACT trial results -- nab-P (Abraxane) + G was superior to G across all efficacy endpoints, had an acceptable toxicity profile, and is a new standard for the treatment of metastatic PC that could become the backbone for new regimens" |
GN |
Rob Cos |
|
4 |
5/21/2013 9:27:34 PM |
|
| | |
|
177773 |
|
Re: PROLONGED OVERALL SURVIVAL WITH POMALIDOMIDE AND DEXAMETHASONE IN END STAGE MYELOMA |
GN |
JBWIN |
|
2 |
5/21/2013 6:27:03 PM |
|
| | |
|
177772 |
|
MRK is following Celgene: $5 B accelerated share repurchase; stock up sharply today. eom. |
GN |
teflon2000 |
|
|
5/21/2013 5:13:33 PM |
|
| | |
|
177771 |
|
EHA-These findings suggest that AZA might be a potentially effective strategy for relapse of high risk myeloid malignancies post allo-HSCT, without unexpected toxicities or de novo GVHD |
GN |
Rob Cos |
|
6 |
5/21/2013 4:07:39 PM |
|
| | |
|
177770 |
|
EHA-AML patients treated with AZA (Vidaza) do better clinically than those patients who physicians elect to treat with DEC (Dacogen) based on statistically significant longer OS and fewer hospitalizations |
GN |
Rob Cos |
|
5 |
5/21/2013 4:06:09 PM |
|
| | |
|
177769 |
|
EHA-PROLONGED OVERALL SURVIVAL WITH POMALIDOMIDE AND DEXAMETHASONE IN END STAGE MYELOMA |
GN |
Rob Cos |
|
5 |
5/21/2013 4:02:59 PM |
|
| | |
|
177768 |
|
EHA-POM has shown activity in MM pts refractory to LEN/BORT. POM + LoDEX significantly extended PFS & OS vs. HiDEX + improvements in clinically relevant QOL measurements over course of Tx. POM + LoDEX should become a standard of care in these pts |
GN |
Rob Cos |
|
4 |
5/21/2013 4:01:53 PM |
|
| | |
|
177767 |
|
POM with or without LoDEX was effective and generally well tolerated in heavily pretreated RRMM patients who had already received LEN and BORT, including patients who had progressed on prior LEN. In general, age had no impact on overall response rate... |
GN |
Rob Cos |
|
3 |
5/21/2013 3:59:13 PM |
|
| | |
|
177766 |
|
POM with or without LoDEX represents a new clinical option for pts with advanced RRMM, including pts with LEN and BORT refractory disease. AEs were predictable and manageable. Updated data with extended follow-up will be presented at the meeting. |
GN |
Rob Cos |
|
3 |
5/21/2013 3:58:11 PM |
|
| | |
|
177765 |
|
Lenalidomide as initial therapy of elderly pts with CLL induced responses that are durable, with 57% of pts maintaining their response for more than 3 years |
GN |
Rob Cos |
|
5 |
5/21/2013 3:56:56 PM |
|
| | |
|
177764 |
|
EHA-Combination CRd therapy followed by extended LEN dosing in newly diagnosed MM patients show deep response rates corroborated by MRD assays and tolerable side effects. |
GN |
Rob Cos |
|
3 |
5/21/2013 3:55:48 PM |
|
| | |
|
177763 |
|
EHARelapsed/refractory MCL pts showed a consistent & predictable safety profile among 3 ph II studies of single-agent lenalidomide. Response to lenalidomide was rapid & durable in heavily pretreated pts, incl pts who received prior bortezomib |
GN |
Rob Cos |
|
3 |
5/21/2013 3:54:31 PM |
|
| | |
|
177762 |
|
EHA-LOW-DOSE LENALIDOMIDE PLUS LOW DOSE CYTARABINE INDUCE COMPLETE REMISSION THAT CAN BE PREDICTED BY GENETIC PROFILING IN VERY ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS. |
GN |
Rob Cos |
|
4 |
5/21/2013 3:53:26 PM |
|
| | |
|
177761 |
|
EHA EU post approval study in RRMM " Incidence of significant VTE was lower than observed in previous series. The incidence of SPM across all cohorts was 1%" (Remember MM-020 is Rev-dex no melphalan) |
GN |
Rob Cos |
|
3 |
5/21/2013 3:51:53 PM |
|
| | |
|
177760 |
|
EHA "With a still limited follow-up time, our data compare favorably with historical R-CHOP21 data. LR-CHOP21 is able to induce a high 2-yr PFS (73%) and it is effective also in poor risk patients (65%). The addition of lenalidomide to R-CHOP21 is safe wi |
GN |
Rob Cos |
|
4 |
5/21/2013 3:49:13 PM |
|
.
